Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 8/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
| ▸ | MDK | P21741 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185421 | 0.90 | FGF2 (0.43) | PTPN1PTPN2NT5ELGALS3CDC25B | |
| SCHEMBL3756883 | 0.89 | NT5E (0.43) | PTPN1PTPN2NT5ECDC25BPTPN6 | |
| SCHEMBL27002581 | 0.89 | NT5E (0.43) | PTPN1PTPN2NT5ECDC25BPTPN6 | |
| SCHEMBL3756881 | 0.89 | NT5E (0.43) | PTPN1PTPN2NT5ECDC25BPTPN6 | |
| SCHEMBL4178365 | 0.89 | NT5E (0.41) | PTPN1PTPN2NT5ESSTR1SSTR2 | |
| SCHEMBL26102300 | 0.86 | SSTR1 (0.42) | PTPN1PTPN2NT5ESSTR1SSTR2 | |
| SCHEMBL6553337 | 0.86 | CYP3A4 (0.41) | NT5ELGALS3 | |
| SCHEMBL6553329 | 0.86 | CYP3A4 (0.41) | NT5ELGALS3 | |
| SCHEMBL3625228 | 0.85 | LGALS3 (0.43) | PTPN1PTPN2NT5ESSTR1SSTR2 | |
| SCHEMBL26506298 | 0.85 | LGALS3 (0.43) | PTPN1PTPN2NT5ESSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176970-A1 | Preparation of Thiosugars and Their Use | GLYCOFORM LIMITED (GB) | 2009-07-09 | — | — | US | disclosed |
| EP-2007782-A2 | THE PREPARATION OF THIOSUGARS AND THEIR USE | Glycoform Limited (GB) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007091040-A2 | THE PREPARATION OF THIOSUGARS AND THEIR USE | GLYCOFORM LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176970-A1 | Preparation of Thiosugars and Their Use | TST, TREH, FUT6 | PTPN1 2222/4885PTPN2 1978/4885NT5E 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.